-
公开(公告)号：US20170174764A1
公开(公告)日：2017-06-22
申请号：US15127023
申请日：2015-03-26
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Irun R. COHEN , Nir FRIEDMAN , Asaf MADI , Eric SHIFRUT , Shlomit REICH-ZELIGER , Asaf PORAN
IPC: C07K16/28
CPC classification number: C07K16/2809 , A61K39/0008 , A61K2039/505
Abstract: The present invention provides isolated peptides derived from TCR CDR3 segments, antibodies which recognize them, pharmaceutical compositions comprising them and methods of their use for modulating self-immunity.
-
公开(公告)号：US20200225223A1
公开(公告)日：2020-07-16
申请号：US16748001
申请日：2020-01-21
Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
Inventor： Irun R. COHEN , Eytan DOMANY , Francisco Javier QUINTANA , Guy HED , Gad GETZ
IPC: G01N33/564 , G16B20/00 , G01N33/68
Abstract: Method, system and an article of manufacture for clustering and thereby identifying predefined antigens reactive with undetermined immunoglobulins of sera derived from patient subjects in need of diagnosis of disease or monitoring of treatment.
-
公开(公告)号：US20200225222A1
公开(公告)日：2020-07-16
申请号：US16650894
申请日：2018-09-17
Applicant: IMMUNARRAY LTD. , YEDA RESEARCH AND DEVELOPMENT CO. LTD.
Inventor： Rachel SOREK , Keren JAKOBI-BROOK , Pennina SAFER , Irun R. COHEN
IPC: G01N33/564 , G16B20/20 , G16B25/30 , G16B40/20
Abstract: Assays, kits and methods useful in the field of systemic lupus erythematosus (SLE) diagnosis and management for determining and providing SLE treatment adjustment include methods for detecting SLE resolution and for adjusting treatment in a subject hitherto diagnosed as having SLE.
-
公开(公告)号：US20230045855A1
公开(公告)日：2023-02-16
申请号：US17936729
申请日：2022-09-29
Applicant: YEDA RESEARCH AND DEVELOPMENT CO., LTD.
Inventor： Rachel SOREK , Keren JAKOBI-BROOK , Pennina SAFER , Irun R. COHEN
IPC: G01N33/564 , G01N33/577
Abstract: Assays and methods for diagnosing and treating autoimmune diseases. Particularly, the invention provides methods for differential diagnosis of specific autoimmune diseases, including autoimmune rheumatic disorders.
-
公开(公告)号：US20160069896A1
公开(公告)日：2016-03-10
申请号：US14652425
申请日：2013-12-16
Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
Inventor： Irun R. COHEN , Eytan DOMANY , Ittai FATTAL , Noam SHENTAL
IPC: G01N33/68
CPC classification number: G01N33/6854 , G01N33/564 , G01N2800/104 , G01N2800/60
Abstract: Methods and kits for diagnosing systemic lupus erythematosus (SLE) or scleroderma in a subject are provided. Particularly, the present invention relates to a specific antibody reactivity profile useful in diagnosing SLE or scleroderma in a subject.
Abstract translation: 提供了用于诊断受试者系统性红斑狼疮（SLE）或硬皮病的方法和试剂盒。 特别地，本发明涉及可用于诊断受试者中的SLE或硬皮病的特异性抗体反应性分布。
-
Patent Agency Ranking
公开(公告)号：US20150297693A1
公开(公告)日：2015-10-22
申请号：US14754835
申请日：2015-06-30
Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
Inventor： Johannes HERKEL , Irun R. COHEN , Varda ROTTER , Ansgar W. LOHSE , Neta EREZ , Avishai MIMRAN , Na'aman KAM
IPC: A61K39/00
CPC classification number: A61K39/0008 , A61K38/00 , A61K39/0005 , C07K7/06 , C07K7/08 , C07K14/435
Abstract: The present invention relates to peptides capable of inhibiting cellular and immune stress responses in a eukaryotic cell. The invention provides compositions and methods for the treatment of human degenerative diseases and inflammation, utilizing these peptides.
Abstract translation: 本发明涉及能够抑制真核细胞中的细胞和免疫应答反应的肽。 本发明提供了利用这些肽治疗人退行性疾病和炎症的组合物和方法。
-
7.发明申请公开(公告)号：US20220003762A1
公开(公告)日：2022-01-06
申请号：US17332178
申请日：2021-05-27
Applicant: YEDA RESEARCH AND DEVELOPMENT CO., LTD.
Inventor： Rachel SOREK , Keren JAKOBI , Pennina SAFER , Anat REINER-BENAIM , Irun R. COHEN
IPC: G01N33/564 , G01N33/68 , G16B40/20
Abstract: Methods and kits for diagnosing or monitoring systemic lupus erythematosus (SLE) in a subject are provided. Particularly, the present invention relates to a specific antibody reactivity profile useful in diagnosing or monitoring SLE in a subject.
-
公开(公告)号：US20210041455A1
公开(公告)日：2021-02-11
申请号：US17081013
申请日：2020-10-27
Inventor： Eran OVADIA , Irun R. COHEN , Johannes HERKEL , Raanan MARGALIT , Meirav PEVSNER-FISCHER
IPC: G01N33/68 , A61K38/18 , G01N33/543 , A61K38/30 , C07K7/06 , A61K31/343 , A61K45/06 , A61K38/08
Abstract: The present invention relates to uses of a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, analogues and derivatives thereof, for the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS). The present invention further provides a method for assessing responsiveness to treatment with the peptide of the invention. In addition, the present invention relates to prognosis of ALS progression, using Akt and phosphorylated Akt as biomarkers.
-
公开(公告)号：US20200264172A1
公开(公告)日：2020-08-20
申请号：US16751831
申请日：2020-01-24
Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
Inventor： Irun R. COHEN , Eytan DOMANY , Noam SHENTAL , Ittai FATTAL
IPC: G01N33/564 , A61K31/711 , C12Q1/6883
Abstract: Methods and kits for diagnosing systemic lupus erythematosus (SLE) in a subject are provided. Particularly, the present invention relates to specific oligonucleotide antibody reactivities useful in diagnosing SLE in a subject.
-
10.发明申请公开(公告)号：US20190204340A1
公开(公告)日：2019-07-04
申请号：US16352879
申请日：2019-03-14
Inventor： Eran OVADIA , Irun R. COHEN , Johannes HERKEL , Raanan MARGALIT , Meirav PEVSNER-FISCHER
IPC: G01N33/68 , G01N33/543 , A61K31/343 , A61K45/06 , C07K7/06 , A61K38/30 , A61K38/18 , A61K38/08
CPC classification number: G01N33/6854 , A61K31/343 , A61K38/08 , A61K38/1808 , A61K38/1825 , A61K38/1833 , A61K38/1841 , A61K38/185 , A61K38/1866 , A61K38/1891 , A61K38/30 , A61K45/06 , C07K7/06 , G01N33/54306 , G01N33/6896 , G01N2800/28 , G01N2800/52 , A61K2300/00
Abstract: The present invention relates to uses of a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, analogues and derivatives thereof, for the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS). The present invention further provides a method for assessing responsiveness to treatment with the peptide of the invention. In addition, the present invention relates to prognosis of ALS progression, using Akt and phosphorylated Akt as biomarkers.
-
-
-
-
-
-
-
-
-
Search Results
13
records
(took 0.02 seconds)
